ArticleEJNMMI research2026
Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadium-223 (Ra-223) has been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with predominant osseous metastases. PSA flare phenomenon with Ra-223 limits its use as a prognostic tool to predict treatment response. Currently, there is a lack of diagnostic tools to predict treatment response to Ra-223. Therefore, we sought to investigate the role of mid treatment C-11 choline PET/CT scan in predicting overall response to Ra-223. In a single institute retrospective study, we identified 32 patients who were treated with a full course of 4–6 cycles of Ra-223 and were evaluated with PSA, and C-11 choline PET scan before treatment, at mid-treatment point, and after complete course of Ra-223 between 2013 and 2018. Ra-223 was used as a salvage therapy for their predominant bone disease after failing chemotherapy and 2nd generation hormone therapy. Blind repeat radiographic evaluation of patients’ scans has been done by a radiologist specialized in nuclear medicine. Favorable response was defined by achieving partial response or stable disease on imaging, while unfavorable response was defined by showing progressive disease on imaging.
resultsMean age (± SD) at starting Radium223 was 67.6 (± 7.1) years, median (IQR) primary Gleason score was 9 (8–9), and median (IQR) pretreatment PSA was 13.5 (5.4–39.6) ng/ml. 78% of the patients (n = 25) completed 6 cycles of Ra-223, and 15% of the patients (n = 5) completed 5 cycles while 6% (n = 2) received only 4 cycles. At mid treatment scanning, 25% of the patient (n = 8) showed favorable response (Group A), while 75% of the patients (n = 24) showed unfavorable response (B). After complete course of treatment, 50% of patients (n = 4) in Group (A) continued to show favorable response, versus only 8.3% of patients (n = 2) in Group (B) showed favorable response (p-value = 0.023).
conclusionMid treatment evaluation with C-11 choline PET/CT scan can predict overall response to Radium 223. Patients with progressive disease at mid- treatment evaluation are very likely not going to respond to their treatment. Further studies and clinical trials are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.